Intra-Cellular Therapies ended the year 2021 with a big achievement. On December 20, 2021, Dr. Sharon Mates, Chairman, and CEO…
Browsing: Feature Stories
According to the American Academy of Dermatology Association, one in five Americans will develop skin cancer in their lifetime. Skin…
LambdaVision is a biotech company, that is designing and developing a protein-based artificial retina. This retina will utilize a light-activated protein, bacteriorhodopsin to restore function sight to those who are blind due to retinal degenerative diseases, including age-related macular degeneration (AMD) and retinitis pigmentosa (RP).
In 2021, Cognition Therapeutics completed two important clinical study trials. The first was SNAP which measured the displacement of amyloid beta oligomers into the cerebrospinal fluid (CSF). This study confirmed the mechanism of action of their lead candidate CT1812. CT1812 is orally delivered and designed to bind selectively to the sigma-2 receptor complex to restore damaged cellular processes. The second trial, SPARC, showed evidence that CT1812 slowed brain atrophy in mild-to-moderate Alzheimer patients. Currently, there are 7 ongoing clinical trials with CT1812. Cognition Therapeutics has also achieved over $117 million in funding from the National Institute on Aging. Lisa Ricciardi, CEO, and president of Cognition Therapeutics reported, “2021 was a transformative year for Cognition Therapeutics. We completed our IPO, secured significant additional non-dilutive funding, and progressed our pipeline creating a product portfolio in addition to our lead candidate CT1812.”
Scientists are exploring the effects of epigenetic modifications and errors on gene function, protein production, and human health.Epigenetic modification opens many doors to new classes of therapeutics. Autoimmune disorders are many times caused by genetic mutations which behave similarly to the epigenome. Developing drugs that can manipulate epigenomic errors will offer a promising cure for cancer and other autoimmune diseases.Currently, companies like Chroma, Vertex, Twenty-Eight Seven are making great advances in epigenetic therapy.
On October 8, 2021, the FDA approved Rethymic, marking a life-changing day of hope for children with congenital athymia and…
EpiBone’s groundbreaking technology revolves around the bioreactor. Over 20 years of research and experience, the bioreactor was made to cultivate a nourishing and supportive environment for bone scaffolds to grow in. This three-step process consists of imaging and stem cell extraction, graft and bioreactor design, and finally bone growth. Using a CT scan, the exact 3D size and shape of the bone for the patient are determined.
With immense participation from companies dedicating their resources to finding a cure for Covid-19, Aetion has recently partnered with the…
Lung cancer leads in mortality ahead of all other cancer deaths in both developed and undeveloped countries and is the…
Starting a challenging role while under the circumstances of a global pandemic, Kathryn Schubert was announced President and CEO of…
